Publish date: 29 May 2024
The MHRA has asked organisations to implement new regulatory measures on the use of Valproate containing medicines. This follows a comprehensive review of safety data, advice from the Commission on Human Medicines and an expert group, and liaison with clinicians and organisations.
Due to the significant changes in Valproate medicines regulatory measures, pathways for male and female initiation and ongoing reviews have been created to support our clinicians. Find out more on the YourSpace.
Patient information booklets, alert cards and resources can be found GOV.UK.